FTO and acute myeloid leukemia: Mimicking FTO deletion, an FB23-2 structure-based design dramatically suppresses the progression of both human and mice AML cell lines, which provides a promising targeted therapeutic strategy for small-molecule inhibitors as an effective treatment of AML via targeting oncogenic FTO (92).